EHA 2025 | Mezigdomide in novel combinations reactivates the immune system in patients with R/R myeloma

So at the meeting we’re presenting our updates on the combination of mezigdomide combined with tazemetostat and in a separate arm combined with trametinib, indeed also with dexamethasone in both combinations. So basically mezigdomide-dexamethasone-tazemetostat and mezigdomide-dexamethasone-trametinib. 

And essentially what we’ve seen with this platform is that with the tazemetostat containing combination the response rate has been quite encouraging at around 65 to 70 percent. And actually remarkably with the trametinib combination our data are actually continuing to improve over time and we’re seeing a response rate of between 75 and 80 percent or thereabouts in this very heavily pretreated population and with a very favorable safety profile which we think is encouraging. 

So I think the real takeaway from the presentation here at the meeting and my co-investigator, principal investigator, Luciano Costa is the primary author of our work, is that the combination is not only active and well-tolerated, but as you point out, we’ve done a very comprehensive look at immune profiling and shown that there’s activation of key T-cell subsets. So this is a really relevant strategy in the era of immunotherapy because as we face the challenges of immune exhaustion and patients having had prior B-cell specific treatment and CAR-T therapy, as patients have in this particular study, and unfortunately those treatments have failed them, they’re then in a position to take advantage of the mezigdomide based therapy and benefit substantially from that.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.